Alvotech (ALVO) Files First Known EMA Bid for Eylea 8mg Biosimilar

Alvotech (ALVO) submitted AVT29, a biosimilar to Eylea 8 mg, to the EMA. The company claims this is the first global regulatory submission for an Eylea 8 mg biosimilar, expanding its aflibercept strategy beyond the approved 2mg version.

Original reporting
Published Oct 14, 2026, 8:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 8:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alvotech (ALVO) Files First Known EMA Bid for Eylea 8mg Biosimilar — source image
Decision brief

The 30-second read

$ALVOBullishMed
01

Why it matters

The EMA filing is the first of its kind for an 8 mg Eylea biosimilar, representing a material regulatory milestone.

02

Market read

The submission could catalyze a price move if the EMA signals a positive outlook, affecting biotech and ophthalmology sectors.

03

What to watch

Potential competition from other biosimilar candidates and pricing pressure in the ophthalmology market.

Relevance 8/10Novelty 8/10Timing: today

Background

Alvotech is expanding its aflibercept biosimilar portfolio beyond the approved 2 mg version.

Company-level read

Ticker impact

$ALVOBullishHigh confidence
Context

Alvotech filed its first EMA submission (AVT29) for an Eylea 8 mg biosimilar.

Expected impact

likely upside as investors price in potential approval and market expansion.

Evidence & confidence

First known EMA bid for this product class; approval would significantly broaden Alvotech's aflibercept portfolio.

Market effects

May boost sentiment for biosimilar developers and the broader ophthalmology drug space.

Could raise visibility of Icelandic biotech firms in European markets.

Adds to the pipeline of anti‑VEGF biosimilars competing with Roche's Eylea globally.

Counterpoint

Regulatory approval is uncertain; EMA may request additional data, delaying any upside.

Key entities

  • Alvotech

    Icelandic biotech focused on biosimilars.

Related articles

$ALVOMed

Alvotech (ALVO) Q3 2026 Earnings Call Transcript

Alvotech (ALVO) reported Q3 2026 earnings, highlighting FDA approvals, strong revenue growth, and strategic partnerships. Revenue for the first 9 months was $323 million, with EBITDA of $78 million, up 15% year-over-year. The company expects Q4 to be its strongest quarter and anticipates performance to trend towards the lower end of its stated range.

$ALVOMed

What Alvotech (ALVO) Said on Its Q3 Earnings Call

Alvotech (ALVO) reported Q3 revenue down 23% YoY, citing production delays and licensing timing. Adjusted EBITDA rose 15% to $78M. CEO maintained guidance despite delayed approvals. FDA approved manufacturing changes, doubling capacity. Cash fell to $61M due to working capital. Company expects Q4 cash-flow positivity and 2027 EBITDA improvement.

$ALVOHighAI 8/10

Alvotech (ALVO): Financial results for 9M

Alvotech (ALVO) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing i